Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001294174 | SCV001483003 | uncertain significance | Exostoses, multiple, type 2 | 2020-09-11 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001294174 | SCV004559218 | uncertain significance | Exostoses, multiple, type 2 | 2023-07-18 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 325 of the EXT2 protein (p.Arg325Trp). This variant is present in population databases (rs145611597, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with EXT2-related conditions. ClinVar contains an entry for this variant (Variation ID: 998352). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt EXT2 protein function. |
Fulgent Genetics, |
RCV005040135 | SCV005683550 | uncertain significance | Exostoses, multiple, type 2; Seizures-scoliosis-macrocephaly syndrome | 2024-05-15 | criteria provided, single submitter | clinical testing |